Trial · NCT03118739
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
121 to 140 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Baseline eGFR | Verinurad 9 mg+Febuxostat 80 mg | 59.2 | Standard Deviation 25.25 | mL/min/1.73m2 | |
| Baseline eGFR | Placebo | 68.1 | Standard Deviation 23.15 | mL/min/1.73m2 | |
| Baseline UACR | Verinurad 9 mg+Febuxostat 80 mg | 459.05 | Standard Deviation 824.731 | mg/g | |
| Baseline UACR | Placebo | 411.55 | Standard Deviation 547.816 | mg/g | |
| Baseline Serum Uric Acid (sUA) | Verinurad 9 mg+Febuxostat 80 mg | 7.51 | Standard Deviation 1.558 | mg/dL | |
| Baseline Serum Uric Acid (sUA) | Placebo | 7.02 | Standard Deviation 0.813 | mg/dL | |
| Baseline Serum Creatinine | Verinurad 9 mg+Febuxostat 80 mg | 1.40 | Standard Deviation 0.595 | mg/dL | |
| Baseline Serum Creatinine | Placebo | 1.19 | Standard Deviation 0.362 | mg/dL | |
| Baseline Serum Cystatin-C | Verinurad 9 mg+Febuxostat 80 mg | 1.579 | Standard Deviation 0.5274 | mg/L | |
| Baseline Serum Cystatin-C | Placebo | 1.313 | Standard Deviation 0.3532 | mg/L | |
| Baseline Serum High-sensitivity C-reactive Protein | Verinurad 9 mg+Febuxostat 80 mg | 0.410 | Standard Deviation 0.3670 | mg/dL | |
| Baseline Serum High-sensitivity C-reactive Protein | Placebo | 0.358 | Standard Deviation 0.2506 | mg/dL | |
| Baseline MRI Variables - Kidney Cortex T2 Star | Verinurad 9 mg+Febuxostat 80 mg | 81.13 | Standard Deviation 12.995 | ms | |
| Baseline MRI Variables - Kidney Cortex T2 Star | Placebo | 82.31 | Standard Deviation 11.625 | ms | |
| Baseline MRI Variables - LV End-diastolic Volume | Verinurad 9 mg+Febuxostat 80 mg | 161.47 | Standard Deviation 37.766 | mL | |
| Baseline MRI Variables - LV End-diastolic Volume | Placebo | 161.50 | Standard Deviation 32.639 | mL | |
| Baseline MRI Variables - LV Ejection Fraction | Verinurad 9 mg+Febuxostat 80 mg | 59.77 | Standard Deviation 7.869 | % (percentage of LV volume) | |
| Baseline MRI Variables - LV Ejection Fraction | Placebo | 60.19 | Standard Deviation 6.134 | % (percentage of LV volume) | |
| Baseline MRI Variables - LV End-systolic Volume | Verinurad 9 mg+Febuxostat 80 mg | 66.43 | Standard Deviation 26.089 | mL | |
| Baseline MRI Variables - LV End-systolic Volume | Placebo | 64.63 | Standard Deviation 17.977 | mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03118739/results?page=7